Results 161 to 170 of about 728,389 (310)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore   +16 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

Resilience Practices and Post‐Traumatic Growth Among Sudanese IDPs

open access: yesConflict Resolution Quarterly, EarlyView.
ABSTRACT In this paper we examine the resilience of internally displaced persons (IDPs) in Sudan who have endured various forms of suffering resulting from being targeted or trapped by militants involved in large‐scale violence. Upon escaping the conflict zones, the civilians exhibit strength, adaptability, and wisdom in the face of various threats to ...
Karina Korostelina   +2 more
wiley   +1 more source

Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota   +8 more
wiley   +1 more source

Multivariate Trajectories of Eating Disorder Symptoms and Weight Status in 10‐ to 17‐Year‐Old Children and Adolescents

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) often emerge in adolescence, but developmental trajectories across different core features remain largely unclear. Method The prospective, community‐based study included N = 898 participants aged 9.5–17.5 years (47.6% female, age 11.8 ± 1.4 years) with annual follow‐up over 2–6 (3.4 ± 1.2) years.
Anja Hilbert   +5 more
wiley   +1 more source

A Meta‐Analysis and Systematic Review of Single‐Session Interventions for Eating Disorders

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Background There is a critical gap between the need for eating disorder (ED) treatment and provider availability. Single‐Session Interventions (SSIs) are structured programs intentionally designed for a single client encounter and show promise for filling ED‐treatment and prevention gaps by enhancing accessibility of evidence‐based ...
Sonakshi Negi   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy